PATENT CLAIM ANALYSIS

Application Number: 16106104
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-02
Patent Classification: ["514", "301000"]

Abstract:
The present invention is directed to 5-fluoro-C-(aryl or hetercyclyl)-glycoside derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by SGLT activity, more particularly dual SGLT1/2 activity.

Claim (Index 25):
A process as in  claim 23 , wherein the compound of formula (V-S) is (3R,4R,5R,6R)-3,4-bis((tert-butyldimethylsilyl)oxy)-6-(((tert-butyldimethylsilyl)oxy)methyl)-5-fluorotetrahydro-2H-pyran-2-one.

Metadata:
- Claim Count in Document: 47.0
- Percentile: 96.0
- Lexical Diversity: 1.08108
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14593071', '16059072', '16059074', '13634597', '14122836']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8155427228917309
- 35 USC 102 Novelty (BERT): 0.5316561188098909
- Combined Prediction Score: 0.7871540624835469
- Mean Citation Score: 351.143048
- Max Citation Score: 357.37866
- Similarity Product: 250.1337233390093

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test